Cargando…

2152. Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections

BACKGROUND: Infection is a common complication following implantation of an LVAD. The purpose of this study was to characterize the epidemiology and clinical outcomes of infections in patients who received the HeartWare LVAD, a newer intrapericardial device. METHODS: Adult patients with a HeartWare...

Descripción completa

Detalles Bibliográficos
Autores principales: Hershberger, Todd E, Kaye, Keith S, Chenoweth, Carol, Petty, Lindsay, Butler, Simona O, Clark, Angela M, Eschenauer, Gregory, Albin, Owen, Pagani, Francis D, Patel, Twisha S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252392/
http://dx.doi.org/10.1093/ofid/ofy210.1808
_version_ 1783373253139496960
author Hershberger, Todd E
Kaye, Keith S
Chenoweth, Carol
Petty, Lindsay
Butler, Simona O
Clark, Angela M
Eschenauer, Gregory
Albin, Owen
Pagani, Francis D
Patel, Twisha S
author_facet Hershberger, Todd E
Kaye, Keith S
Chenoweth, Carol
Petty, Lindsay
Butler, Simona O
Clark, Angela M
Eschenauer, Gregory
Albin, Owen
Pagani, Francis D
Patel, Twisha S
author_sort Hershberger, Todd E
collection PubMed
description BACKGROUND: Infection is a common complication following implantation of an LVAD. The purpose of this study was to characterize the epidemiology and clinical outcomes of infections in patients who received the HeartWare LVAD, a newer intrapericardial device. METHODS: Adult patients with a HeartWare LVAD implanted between 2009 and 2017 at Michigan Medicine were screened for inclusion. LVAD-associated infection was defined using INTERMACS criteria. Patients were followed from device implantation to either infection, death, heart transplantation, device exchange, or last known follow-up to date. Exclusions included implantation of a right-sided VAD, alone or in combination with an LVAD. The primary outcomes were the incidence of LVAD-associated infections per 1,000 device days and per 100 person-years. RESULTS: Of the 183 patients included, 43 (23.5%) developed an LVAD-associated infection with incidence rates of 0.39 infections per 1,000 device days and 14.3 infections per 100 patient years. The median time to infection was 305 days (IQR, 172–581). Staphylococcus spp. (26%) and Streptococcus spp. (20%) were the most common causative pathogens identified. The results of a univariate analysis for infection are shown in Figure 1. There were no statistically significant differences in all-cause mortality (40% vs. 17%, P = 0.08) and incidence of heart transplantation (19% vs. 34%, P = 0.09) between those with infection and those without infection; the number of hospital readmissions were more common in patients with infection (median, 4 vs. 2, P < 0.01). CONCLUSION: LVAD-associated infection remains a major complication among recipients of the HeartWare LVAD, with about one-quarter of patients developing infection over time despite improved device design. Infection contributes to the increased hospitalizations seen in this population. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6252392
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62523922018-11-28 2152. Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections Hershberger, Todd E Kaye, Keith S Chenoweth, Carol Petty, Lindsay Butler, Simona O Clark, Angela M Eschenauer, Gregory Albin, Owen Pagani, Francis D Patel, Twisha S Open Forum Infect Dis Abstracts BACKGROUND: Infection is a common complication following implantation of an LVAD. The purpose of this study was to characterize the epidemiology and clinical outcomes of infections in patients who received the HeartWare LVAD, a newer intrapericardial device. METHODS: Adult patients with a HeartWare LVAD implanted between 2009 and 2017 at Michigan Medicine were screened for inclusion. LVAD-associated infection was defined using INTERMACS criteria. Patients were followed from device implantation to either infection, death, heart transplantation, device exchange, or last known follow-up to date. Exclusions included implantation of a right-sided VAD, alone or in combination with an LVAD. The primary outcomes were the incidence of LVAD-associated infections per 1,000 device days and per 100 person-years. RESULTS: Of the 183 patients included, 43 (23.5%) developed an LVAD-associated infection with incidence rates of 0.39 infections per 1,000 device days and 14.3 infections per 100 patient years. The median time to infection was 305 days (IQR, 172–581). Staphylococcus spp. (26%) and Streptococcus spp. (20%) were the most common causative pathogens identified. The results of a univariate analysis for infection are shown in Figure 1. There were no statistically significant differences in all-cause mortality (40% vs. 17%, P = 0.08) and incidence of heart transplantation (19% vs. 34%, P = 0.09) between those with infection and those without infection; the number of hospital readmissions were more common in patients with infection (median, 4 vs. 2, P < 0.01). CONCLUSION: LVAD-associated infection remains a major complication among recipients of the HeartWare LVAD, with about one-quarter of patients developing infection over time despite improved device design. Infection contributes to the increased hospitalizations seen in this population. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6252392/ http://dx.doi.org/10.1093/ofid/ofy210.1808 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Hershberger, Todd E
Kaye, Keith S
Chenoweth, Carol
Petty, Lindsay
Butler, Simona O
Clark, Angela M
Eschenauer, Gregory
Albin, Owen
Pagani, Francis D
Patel, Twisha S
2152. Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections
title 2152. Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections
title_full 2152. Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections
title_fullStr 2152. Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections
title_full_unstemmed 2152. Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections
title_short 2152. Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections
title_sort 2152. epidemiology and clinical outcomes of contemporary, third-generation left ventricular assist device (lvad) infections
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252392/
http://dx.doi.org/10.1093/ofid/ofy210.1808
work_keys_str_mv AT hershbergertodde 2152epidemiologyandclinicaloutcomesofcontemporarythirdgenerationleftventricularassistdevicelvadinfections
AT kayekeiths 2152epidemiologyandclinicaloutcomesofcontemporarythirdgenerationleftventricularassistdevicelvadinfections
AT chenowethcarol 2152epidemiologyandclinicaloutcomesofcontemporarythirdgenerationleftventricularassistdevicelvadinfections
AT pettylindsay 2152epidemiologyandclinicaloutcomesofcontemporarythirdgenerationleftventricularassistdevicelvadinfections
AT butlersimonao 2152epidemiologyandclinicaloutcomesofcontemporarythirdgenerationleftventricularassistdevicelvadinfections
AT clarkangelam 2152epidemiologyandclinicaloutcomesofcontemporarythirdgenerationleftventricularassistdevicelvadinfections
AT eschenauergregory 2152epidemiologyandclinicaloutcomesofcontemporarythirdgenerationleftventricularassistdevicelvadinfections
AT albinowen 2152epidemiologyandclinicaloutcomesofcontemporarythirdgenerationleftventricularassistdevicelvadinfections
AT paganifrancisd 2152epidemiologyandclinicaloutcomesofcontemporarythirdgenerationleftventricularassistdevicelvadinfections
AT pateltwishas 2152epidemiologyandclinicaloutcomesofcontemporarythirdgenerationleftventricularassistdevicelvadinfections